| abstract |
Disclosed herein is an aqueous pharmaceutical formulation comprising denosumab or another human anti-RANKL monoclonal antibody or part thereof and pH characteristics, a buffer system, and an amino acid aggregation inhibitor. It also reveals the appearance of the formulation when in use, such as in single-use vials, single-use syringes, or glass containers; methods of using such formulations and products to prevent or treat disease; and related sets. |